title: Mosaic chemotherapy strategies for developing ALS/MND therapeutic approaches: beta-2 adrenergic agonists.
authors.affiliation: Department of Neurology, University of Wisconsin Hospital & Clinics, UW Health System, School of Medicine, University of Wisconsin-Madison 53792-5132, USA.
authors.forename: B R
authors.initials: BR
authors.lastname: Brooks
authors.forename: K
authors.initials: K
authors.lastname: Juhasz-Poscine
authors.forename: A
authors.initials: A
authors.lastname: Waclawik
authors.forename: M
authors.initials: M
authors.lastname: Sanjak
authors.forename: D
authors.initials: D
authors.lastname: Belden
authors.forename: K
authors.initials: K
authors.lastname: Roelke
authors.forename: J
authors.initials: J
authors.lastname: Parnell
authors.forename: C
authors.initials: C
authors.lastname: Weasler
mesh_terms: D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy*; D002976:Clenbuterol / Q000627:therapeutic use*; D006801:Humans
chemical_list: D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists; D002976:Clenbuterol